Ignite Creation Date:
2025-12-25 @ 12:24 AM
Ignite Modification Date:
2026-03-04 @ 7:33 AM
Study NCT ID:
NCT06620458
Status:
RECRUITING
Last Update Posted:
2024-11-14
First Post:
2024-04-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Retrospective Study on the Factors of Drug-coated Balloon Restenosis
Sponsor:
Henan Institute of Cardiovascular Epidemiology
Organization:
Study Overview
Official Title:
A Retrospective Study on the Factors of Drug-coated Balloon Restenosis
Status:
RECRUITING
Status Verified Date:
2024-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RE-DCB
Brief Summary:
The purpose of this study is to analyze potential factors post paclitaxel drug-coated balloon angioplasty in patients with Denovo large vessels disease. It includes imaging endpoints and clinical event endpoints. Over 5000 patients are expected to be enrolled.
Detailed Description:
This study is a retrospective analysis that retrospectively reviewed over approximately 5000 patients with de novo-large-vessel disease who underwent paclitaxel drug-coated balloon angioplasty. The study endpoints include cardiovascular adverse events at 1 year (cardiovascular death, cardiovascular events) and coronary angiographic outcomes (primarily late lumen loss, restenosis rate). It primarily focuses on differences in baseline characteristics, lesion features, intracavitary imaging characteristics(Including OCT, IVUS), hemodynamic parameter，and procedural approaches among patients. Over 5000 patients are expected to be enrolled.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: